Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER-Reference-Cited by-同舟云学术

Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER

Published:2008-09 Issue:1 Volume:200 Page:109-114
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Polisecki Eliana,Muallem Hind,Maeda Nobuyo,Peter Inga,Robertson Michele,McMahon Alex D.,Ford Ian,Packard Christopher,Shepherd James,Jukema J. Wouter,Westendorp Rudi G.J.,de Craen Anton J.M.,Buckley Brendan M.,Ordovas Jose M.,Schaefer Ernst J.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference19 articles.

1. A receptor-mediated pathway for cholesterol homeostasis;Goldstein;Science,1986

2. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein;Hobbs;Annu Rev Genet,1990

3. Familial hypercholesterolemia;Goldstein,1995

4. The low-density lipoprotein pathway and its relation to atherosclerosis;Goldstein,1977

5. Quantitative effects of common genetic variations in the 3′UTR of the human LDL-receptor gene and their associations with plasma lipid levels in the Atherosclerosis Risk in Communities study;Muallem;Hum Genet,2007

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of LDLR polymorphisms on lipid levels and atorvastatin’s efficacy in a northern Chinese adult Han cohort with dyslipidemia;Lipids in Health and Disease;2024-04-14

2. Major Genetic Drivers of Statin Treatment Response in African Populations and Pharmacogenetics of Dyslipidemia Through a One Health Lens;OMICS: A Journal of Integrative Biology;2023-11-14

3. HMGCR gene polymorphism is associated with residual cholesterol risk in premature triple-vessel disease patients treated with moderate-intensity statins;BMC Cardiovascular Disorders;2023-06-24

4. Genetics of Lipid Disorders;Metabolic Syndrome;2023

5. Pharmacogenomics of lipid-lowering agents: the impact on efficacy and safety;Personalized Medicine;2022-11-23